valproic acid has been researched along with Invasiveness, Neoplasm in 22 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of valproic acid (VPA) on the viability, apoptosis, and invasiveness of two glioma cells (A172 and T98G) and the underlying mechanisms were studied." | 7.78 | Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. ( Chen, Y; Tsai, YH; Tseng, SH, 2012) |
| "In conclusion, co‑treatment of cholangiocarcinoma cells with TSA or VPA and GEM suppressed EMT with tolerable cytotoxicity." | 5.48 | HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells. ( Ji, M; Lee, EJ; Park, SM; Wang, JH, 2018) |
| "Matrigel and Collagen invasion assays were performed to evaluate the effect of several HDACi (Butyrate, Trichostatin A, Valproic acid and Vorinostat) on two human melanoma cell line invasion (A375 and HT-144)." | 3.83 | Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. ( Andrade, R; Aréchaga, J; Arluzea, J; De Wever, O; Díaz-Núñez, M; Díez-Torre, A; Silió, M, 2016) |
| "The effects of valproic acid (VPA) on the viability, apoptosis, and invasiveness of two glioma cells (A172 and T98G) and the underlying mechanisms were studied." | 3.78 | Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. ( Chen, Y; Tsai, YH; Tseng, SH, 2012) |
| "Twenty-six patients with advanced cancer (14 men/12 women), median age of 56 years (range 38-70 years), and a median number of two prior therapies (range 0-12) were enrolled." | 2.80 | Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. ( Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ, 2015) |
| "In a sample of archival human osteosarcoma tumor specimens, expression of Hes1 mRNA was inversely correlated with survival (n=16 samples, p=0." | 2.45 | How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. ( Hughes, DP, 2009) |
| "In conclusion, co‑treatment of cholangiocarcinoma cells with TSA or VPA and GEM suppressed EMT with tolerable cytotoxicity." | 1.48 | HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells. ( Ji, M; Lee, EJ; Park, SM; Wang, JH, 2018) |
| "Four colon cancer cell lines with different phenotypes in regards to tumorigenicity, microsatellite stability and DNA mutation were used." | 1.42 | HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. ( Ji, M; Kim, DS; Kim, KB; Kim, Y; Lee, EJ; Lee, SJ; Park, SM; Sung, R, 2015) |
| "Valproic acid could suppress invasiveness of prostate cancer cell lines PC3 and Du145, possibly through multiple pathways other than the SAMD4 pathway." | 1.40 | Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness. ( Huang, Z; Jiang, W; Jin, X; Wang, M; Wang, Z; Xia, Q; Zhang, Y; Zheng, Y, 2014) |
| "Treatment of breast cancer cells with a demethylating agent and histone deacetylase inhibitors reduced methylation of the CR-1 promoter and reactivated CR-1 mRNA and protein expression in these cells, promoting migration and invasion of breast cancer cells." | 1.39 | Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. ( Baraty, C; Bianco, C; Castro, NP; Gonzales, M; Held, N; Karasawa, H; Rangel, MC; Rollman, K; Salomon, DS; Strizzi, L, 2013) |
| "In this study, primary murine prostate cancer (PCa) cells were derived using the well-established TRAMP model." | 1.39 | Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. ( Bremmer, F; Burfeind, P; Kaulfuss, S; Neesen, J; Opitz, L; Salinas-Riester, G; Schweyer, S; Thelen, P; von Hardenberg, S; Witt, D, 2013) |
| "Malignant pleural mesothelioma is known to be widely resistant to therapy and new treatment strategies are needed." | 1.37 | Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells. ( Asakura, K; Fukutomi, T; Izumi, Y; Kawai, K; Nomori, H; Serizawa, A; Suematsu, M; Wakui, M; Yamauchi, Y, 2011) |
| "Valproic acid (VPA) is an established drug in the long-term therapy of epilepsy." | 1.36 | Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. ( Ferreri, AM; Guerra, F; Orlandi, M; Papi, A; Rocchi, P, 2010) |
| "Using cells and prostate cancer xenograft mouse models, we demonstrate in this study that a combination treatment using the PPARgamma agonist pioglitazone and the histone deacetylase inhibitor valproic acid is more efficient at inhibiting prostate tumor growth than each individual therapy." | 1.33 | Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. ( Abella, A; Annicotte, JS; Berthe, ML; Culine, S; Dubus, P; Fajas, L; Fritz, V; Iankova, I; Iborra, F; Maudelonde, T; Miard, S; Noël, D; Pillon, A; Sarruf, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 17 (77.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valiulytė, I | 1 |
| Curkūnavičiūtė, R | 1 |
| Ribokaitė, L | 1 |
| Kazlauskas, A | 1 |
| Vaitkevičiūtė, M | 1 |
| Skauminas, K | 1 |
| Valančiūtė, A | 1 |
| Wang, JH | 1 |
| Lee, EJ | 2 |
| Ji, M | 2 |
| Park, SM | 2 |
| Sachkova, A | 1 |
| Sperling, S | 1 |
| Mielke, D | 1 |
| Schatlo, B | 1 |
| Rohde, V | 1 |
| Ninkovic, M | 1 |
| Jiang, W | 1 |
| Zheng, Y | 1 |
| Huang, Z | 1 |
| Wang, M | 1 |
| Zhang, Y | 1 |
| Wang, Z | 1 |
| Jin, X | 1 |
| Xia, Q | 1 |
| Bilen, MA | 1 |
| Fu, S | 1 |
| Falchook, GS | 1 |
| Ng, CS | 1 |
| Wheler, JJ | 1 |
| Abdelrahim, M | 1 |
| Erguvan-Dogan, B | 1 |
| Hong, DS | 1 |
| Tsimberidou, AM | 1 |
| Kurzrock, R | 1 |
| Naing, A | 1 |
| Kim, KB | 1 |
| Kim, Y | 1 |
| Sung, R | 1 |
| Lee, SJ | 1 |
| Kim, DS | 1 |
| Artacho-Cordón, F | 1 |
| Ríos-Arrabal, S | 1 |
| Olivares-Urbano, MA | 1 |
| Storch, K | 1 |
| Dickreuter, E | 1 |
| Muñoz-Gámez, JA | 1 |
| León, J | 1 |
| Calvente, I | 1 |
| Torné, P | 1 |
| Salinas, Mdel M | 1 |
| Cordes, N | 1 |
| Núñez, MI | 1 |
| Díaz-Núñez, M | 1 |
| Díez-Torre, A | 1 |
| De Wever, O | 1 |
| Andrade, R | 1 |
| Arluzea, J | 1 |
| Silió, M | 1 |
| Aréchaga, J | 1 |
| Wu, L | 1 |
| Feng, H | 1 |
| Hu, J | 1 |
| Tian, X | 1 |
| Zhang, C | 1 |
| Hughes, DP | 1 |
| Papi, A | 2 |
| Ferreri, AM | 2 |
| Rocchi, P | 1 |
| Guerra, F | 2 |
| Orlandi, M | 2 |
| Yagi, Y | 1 |
| Fushida, S | 1 |
| Harada, S | 1 |
| Kinoshita, J | 1 |
| Makino, I | 1 |
| Oyama, K | 1 |
| Tajima, H | 1 |
| Fujita, H | 1 |
| Takamura, H | 1 |
| Ninomiya, I | 1 |
| Fujimura, T | 1 |
| Ohta, T | 1 |
| Yashiro, M | 1 |
| Hirakawa, K | 1 |
| Wedel, S | 1 |
| Hudak, L | 1 |
| Seibel, JM | 1 |
| Makarević, J | 1 |
| Juengel, E | 1 |
| Tsaur, I | 1 |
| Wiesner, C | 1 |
| Haferkamp, A | 1 |
| Blaheta, RA | 2 |
| Yamauchi, Y | 1 |
| Izumi, Y | 1 |
| Asakura, K | 1 |
| Fukutomi, T | 1 |
| Serizawa, A | 1 |
| Kawai, K | 1 |
| Wakui, M | 1 |
| Suematsu, M | 1 |
| Nomori, H | 1 |
| Chen, Y | 1 |
| Tsai, YH | 1 |
| Tseng, SH | 1 |
| Bianco, C | 1 |
| Castro, NP | 1 |
| Baraty, C | 1 |
| Rollman, K | 1 |
| Held, N | 1 |
| Rangel, MC | 1 |
| Karasawa, H | 1 |
| Gonzales, M | 1 |
| Strizzi, L | 1 |
| Salomon, DS | 1 |
| Witt, D | 1 |
| Burfeind, P | 1 |
| von Hardenberg, S | 1 |
| Opitz, L | 1 |
| Salinas-Riester, G | 1 |
| Bremmer, F | 1 |
| Schweyer, S | 1 |
| Thelen, P | 1 |
| Neesen, J | 1 |
| Kaulfuss, S | 1 |
| McGarry, LC | 1 |
| Winnie, JN | 1 |
| Ozanne, BW | 1 |
| Chen, CL | 1 |
| Sung, J | 1 |
| Cohen, M | 1 |
| Chowdhury, WH | 1 |
| Sachs, MD | 1 |
| Li, Y | 1 |
| Lakshmanan, Y | 1 |
| Yung, BY | 1 |
| Lupold, SE | 1 |
| Rodriguez, R | 1 |
| Annicotte, JS | 1 |
| Iankova, I | 1 |
| Miard, S | 1 |
| Fritz, V | 1 |
| Sarruf, D | 1 |
| Abella, A | 1 |
| Berthe, ML | 1 |
| Noël, D | 1 |
| Pillon, A | 1 |
| Iborra, F | 1 |
| Dubus, P | 1 |
| Maudelonde, T | 1 |
| Culine, S | 1 |
| Fajas, L | 1 |
| Michaelis, M | 1 |
| Natsheh, I | 1 |
| Hasenberg, C | 1 |
| Weich, E | 1 |
| Relja, B | 1 |
| Jonas, D | 1 |
| Doerr, HW | 1 |
| Cinatl, J | 1 |
1 review available for valproic acid and Invasiveness, Neoplasm
| Article | Year |
|---|---|
How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.
Topics: Basic Helix-Loop-Helix Transcription Factors; Bone Development; Bone Neoplasms; Histone Deacetylase | 2009 |
1 trial available for valproic acid and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; L | 2015 |
20 other studies available for valproic acid and Invasiveness, Neoplasm
| Article | Year |
|---|---|
The Anti-Tumorigenic Activity of Sema3C in the Chick Embryo Chorioallantoic Membrane Model.
Topics: Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Glioblastoma; Humans; Neoplasm In | 2019 |
HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; E | 2018 |
Combined Applications of Repurposed Drugs and Their Detrimental Effects on Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cel | 2019 |
Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness.
Topics: Cell Line, Tumor; Cell Movement; Down-Regulation; Enzyme Inhibitors; Humans; Male; Neoplasm Invasive | 2014 |
HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells.
Topics: Cadherins; Carcinoma; Cell Movement; Colonic Neoplasms; Epithelial-Mesenchymal Transition; HCT116 Ce | 2015 |
Valproic acid modulates radiation-enhanced matrix metalloproteinase activity and invasion of breast cancer cells.
Topics: Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Infrared Rays; Matri | 2015 |
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Topics: Antineoplastic Agents; Apoptosis; Butyrates; Cadherins; Cell Line, Tumor; Gene Expression Regulation | 2016 |
Valproic acid (VPA) promotes the epithelial mesenchymal transition of hepatocarcinoma cells via transcriptional and post-transcriptional up regulation of Snail.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Epithelial-Mesenc | 2016 |
Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Topics: Anticonvulsants; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation | 2010 |
Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line.
Topics: Acetylation; Adenocarcinoma, Scirrhous; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western | 2010 |
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Topics: Cell Adhesion; Cell Movement; Drug Therapy, Combination; Enzyme Inhibitors; Everolimus; Histone Deac | 2011 |
Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; | 2011 |
Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms.
Topics: Anticonvulsants; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Movement; Flow Cytometry; Gliom | 2012 |
Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Ca | 2012 |
Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.
Topics: Azacitidine; Binding Sites; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Embryonal; Cell | 2013 |
Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2.
Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cy | 2013 |
Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes.
Topics: Actins; Animals; Blotting, Northern; Blotting, Western; Cadherin Related Proteins; Cadherins; Cell D | 2004 |
Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Topics: Acetylation; Animals; Cell Line, Tumor; Cell Movement; Cell Survival; Coxsackie and Adenovirus Recep | 2006 |
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Topics: Animals; Cadherins; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progressio | 2006 |
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.
Topics: Antigens, Surface; Antineoplastic Agents; Cell Adhesion; Cisplatin; Drug Resistance, Neoplasm; Endot | 2007 |